Medical Devices Startups

DiaMonTech develops a non-invasive, painless optical technology for measuring blood glucose within seconds, offered as a handheld device (still in development), a miniaturized sensor for wearables such as smartwatches (developed with Samsung), and a companion app for tracking glucose, blood pressure, nutrition, activity, weight and medication. The company targets diabetes management and life-sciences applications.

4 investors

DiscureMD is developing a treatment focused on disc degeneration, a leading cause of back pain that affects most adults during their lifetime.

4 investors

Distalmotion develops DEXTER, a surgical robotics system for minimally invasive procedures such as hernia repair, cholecystectomy, and hysterectomy, used by surgeons and clinical teams. Founded as a spin-off from EPFL's Robotics Lab, the company serves the medical device and robotic surgery market in Europe and the United States.

4 investors

Eargo was a hearing aid company that provided high-quality hearing aids and related care services. The company is currently winding down its US operations.

4 investors

Earli develops a biotechnology platform that uses genetic constructs to detect cancer and produce therapeutic proteins by reprogramming cancer cells. The company focuses on oncology diagnostics and therapeutics for cancer patients.

4 investors

Empatica offers an FDA-cleared health monitoring platform combining medical wearables and digital biomarkers to collect continuous, clinical-quality health data from daily life. It serves researchers, clinicians, and pharmaceutical companies for clinical trials and remote patient monitoring across therapeutic areas including neurology and Parkinson's disease.

4 investors

Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases. The company serves healthcare providers, payers, and patients by offering a mechanical hands-free alternative to intravenous treatment.

4 investors

Encellin develops next-generation therapies for patients with chronic unmet clinical needs, using technology originating from Dr. Tejal Desai's laboratory at UCSF that combines micro and nanotechnologies with novel drug delivery approaches. The company focuses on therapeutic delivery platforms and cell-based treatments, particularly for diseases including diabetes and autoimmune conditions.

4 investors

EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies. It is built by a multidisciplinary team with experience in platform and commercial market development.

4 investors

Encora Therapeutics makes the Encora X1, an FDA-cleared, prescription wrist-worn device that uses mechanical neurostimulation to relieve hand tremors in adults with essential tremor. The device is designed as a non-drug option that can be used alone or alongside existing treatment plans.

4 investors

Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.

4 investors

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

4 investors

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

4 investors

Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema. The drug is set to enter Phase IIb clinical trials in 2026.

4 investors

FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care. The company runs clinical trials across Europe and the US for people living with heart failure.

4 investors

Flosonics Medical makes FloPatch, a wireless wearable Doppler ultrasound device that assesses a patient's carotid arterial pulse in real time to give clinicians hemodynamic data for fluid resuscitation decisions. It targets acute care settings, supporting fluid management for patients with sepsis and septic shock.

4 investors

Flow develops technology-based mental health solutions to address depression symptoms and wellness. The company serves individuals seeking mental health treatment through science-backed approaches.

4 investors

Foundation Medicine is a precision medicine company that develops comprehensive genomic profiling and companion diagnostic tests for cancer and other diseases. It serves patients, healthcare providers, and biopharma companies, with tests available across all U.S. states and 45+ countries.

4 investors

Functional Fluidics is a CLIA-certified diagnostic lab offering proprietary red blood cell function biomarker assays, starting with Sickle Cell Disease. It provides contract research services and biomarker testing to clinical providers, pharmaceutical, biotech, and academic partners to support drug development and patient care, with operations in the US and Sub-Saharan Africa.

4 investors

Geneoscopy develops innovative diagnostic technologies for gastrointestinal health, specifically focused on the detection of colorectal cancer. The company serves healthcare providers and patients seeking advanced diagnostic solutions in the medical diagnostics and cancer detection sector.

4 investors

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

4 investors

Gleamer develops AI copilot software for medical imaging that assists radiologists in detecting pathologies and generating diagnostic reports across X-ray, CT, and MRI modalities. The company serves hospitals and radiology groups with CE and FDA-cleared solutions for fracture detection, chest imaging, bone age assessment, and other diagnostic tasks.

4 investors

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

4 investors

GammaTile is an FDA-cleared, bioresorbable collagen tile embedded with radiation sources, implanted during brain tumor removal surgery to deliver targeted radiation at the surgical site. It is indicated for patients with operable brain tumors, including newly diagnosed and recurrent glioblastoma, brain metastases, and recurrent meningiomas.

4 investors